PMGC Holdings (ELAB)
NASDAQ:ELAB
Want to see ELAB full AI Analyst Report?
ELAB Stock Chart & Stats
$1.55
-$0.19(-8.12%)
At close: 4:00 PM EST
$1.55
-$0.19(-8.12%)
Day’s Range― - ―
52-Week Range$1.62 - $309.12
Previous CloseN/A
Volume180.10K
Average Volume (3M)89.87K
Market Cap
$11.17M
Enterprise Value$2.10M
Total Cash (Recent Filing)$5.40M
Total Debt (Recent Filing)$2.64M
Price to Earnings (P/E)―
Beta2.67
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding4,450,547
10 Day Avg. Volume35,159
30 Day Avg. Volume89,868
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.37
Price to Sales (P/S)4.90
P/FCF Ratio-0.45
Enterprise Value/Market Cap0.19
Enterprise Value/Revenue3.57
Enterprise Value/Gross Profit28.12
Enterprise Value/Ebitda-0.29
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Equity Cushion And Moderate LeverageA relatively strong equity base versus assets and only moderate leverage provide a durable financial cushion to absorb operating losses and support near-term strategic activity. This balance-sheet flexibility improves the company's ability to fund integration and development while limiting bankruptcy risk absent further deterioration.
Long-term Aerospace/defense Contracts And CertificationsMulti-year supply agreements, ITAR registration and moves toward AS9100 establish sticky customer relationships and regulatory credentials. These traits raise switching costs, create recurring revenue visibility in defense/aerospace channels, and support margin stability from certified, mission-critical manufacturing work.
Biotech IP And Licensing Expansion Into Animal HealthOut-licensing EL-22/EL-32 for animal health transfers development and commercialization responsibilities to a partner, de-risking clinical spend while opening a larger, more predictable revenue stream via royalties. Coupled with patent filings, this diversifies addressable markets and preserves upside with limited incremental cash burn.
Bears Say
Persistent Negative Operating Cash FlowSustained and worsening cash burn indicates core operations are not self-funding; continual outflows necessitate external capital to maintain operations. Over months this heightens refinancing and dilution risk, constrains discretionary investment, and forces management to prioritize liquidity over long-term R&D or organic growth.
Volatile, Collapsing Revenue TrajectoryA precipitous decline in top-line sales undermines operational leverage and makes future margin recovery uncertain. Volatile revenue complicates planning, reduces predictability for cash generation, and weakens the case that recent acquisitions or new business lines will sustainably offset the legacy revenue decline.
Heavy Reliance On Dilutive, Secured Equity FacilitiesFrequent use of pre-paid, secured equity financings provides liquidity but structurally dilutes shareholders and grants investors security interests and participation rights. These covenants can limit strategic flexibility, concentrate creditor claims on subsidiaries, and raise long-term cost of capital if recurring to preserve operations.
PMGC Holdings News
ELAB FAQ
What was PMGC Holdings’s price range in the past 12 months?
PMGC Holdings lowest stock price was $1.62 and its highest was $309.12 in the past 12 months.
What is PMGC Holdings’s market cap?
PMGC Holdings’s market cap is $11.17M.
When is PMGC Holdings’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were PMGC Holdings’s earnings last quarter?
Currently, no data Available
Is PMGC Holdings overvalued?
According to Wall Street analysts PMGC Holdings’s price is currently Overvalued.
Does PMGC Holdings pay dividends?
PMGC Holdings does not currently pay dividends.
What is PMGC Holdings’s EPS estimate?
PMGC Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PMGC Holdings have?
PMGC Holdings has 4,450,547 shares outstanding.
What happened to PMGC Holdings’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PMGC Holdings?
Currently, no hedge funds are holding shares in ELAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PMGC Holdings
PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of cutting-edge aesthetic medicines and therapeutic products. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. It is also involved in the medical scientific research and development activities, as well as operates investment firms. The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024. PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.
Technical Analysis
Biodexa Pharmaceuticals
―
―
Indaptus Therapeutics
―
InMed Pharmaceuticals
―
CNS Pharmaceuticals
―